Gefitinib
In Stock•Starting at $7 for 250 mg•Purity ≥ 98%
| CAS No. | 184475-35-2 |
|---|---|
| MDL No. | MFCD04307832 |
| MF | C22H24ClFN4O3 |
| MW | 446.90 |
| InChI Key | XGALLCVXEZPNRQ-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| 250 mg | 98% | $7 | In Stock | |
| 1 g | 98% | $9 | In Stock | |
| 5 g | 98% | $23 | In Stock | |
| 10 g | 98% | $40 | In Stock | |
| 25 g | 98% | $92 | In Stock |
Product Information
Gefitinib is a quinazoline derivative substituted with a (3-chloro-4-fluorophenyl)nitrilo group at position 4, a 3-(morpholin-4-yl)propoxy group at position 6, and a methoxy group at position 7. It is an EGFR kinase inhibitor used in the treatment of non-small cell lung cancer. Gefitinib functions as an epidermal growth factor receptor antagonist and antineoplastic agent. It is an aromatic ether, a member of monochlorobenzenes, monofluorobenzenes, secondary and tertiary amino compounds, quinazolines, and morpholines.
| CAS No. | 184475-35-2 |
|---|---|
| Product Name | Gefitinib |
Biological Targets
EGFR
Associated Conditions
germ cell tumor·small cell lung carcinoma·acute myeloid leukemia·breast neoplasm·urinary bladder cancer·
* The information provided here is compiled from public sources and is for reference only.
